Product Disclosures

Reflecting standard oncology practice, which often requires the off-label or investigational use of some products, this educational activity includes information about many drugs. All faculty participating in continuing education activities are expected to disclose the approved or investigational status (related to the subject matter of this activity—malignant melanoma) of all products and devices under discussion. This information, as of the time of printing, is summarized briefly in the table below. In addition, primary references and full prescribing information should be consulted for complete information. Clinicians have the professional responsibility to ensure that drugs are prescribed and used appropriately, based on their own clinical judgment and accepted standards of care.

Generic Name Brand Name Investigational for Malignant Melanoma FDA Approved for Malignant Melanoma FDA Approved for Other Indications
Thalidomide Thalomid X   X
Temozolomide Temodar X   X
IMiD3 Revimid X  

 

Peginterferon alfa-2b PEG-Intron-A X

 

X
Dacarbazine DTIC-Dome

 

X X
Bortezomib Velcade X

 

 

Adapted from Drug Facts and Comparisons. St Louis, Mo: Facts & Comparisons; 2003.